The goal ofthe Translational & Clinical Research Program is to bring new insights from Basic Sciences Programs ofthe Siteman Cancer Center into innovative clinical trials that will have an important impact on improving oncologic care for patients. Our particular emphasis is on utilizing information from Signaling Pathways, (eg FGFR2 in endometrial cancer, NF1 in glioblastoma, and RET in thyroid cancer). Genomics (lung cancer, glioblastoma, prostate cancer and rectal cancer), and Oncologic Imaging (prostate cancer, lung and esophageal cancers, and thyroid cancer) for the design, analysis, and interpretation of clinical research trials and studies. Collaborations with the Prevention and Control Program are also fostered by this program and have resulted in grants, publications and clinical projects from areas including prostate cancer screening and co-morbidity studies. The Translational & Clinical Research Program provides the supporting network for an expanding Developmental Therapeutics Program focused on institutional phase 0,1, and II studies. The program also supports disease-based working groups to develop, review, prioritize, and conduct clinical trials research, with special emphasis on working groups in lung, endometrial, prostate, and Gl cancer, and Neuro-Oncology. Furthermore, the Translational & Clinical Research Program will provide training of investigators at all levels of experience and foster educational opportunities including seminars, courses, retreats, journal clubs, workshops, and work-in-progress meetings. The Translational & Clinical Research Program has 74 members from 15 Departments and 2 Schools. The Program is supported by $24,979,138 in funding of which $11,438,989 in NCI funding and $10,835,323 in other peer reviewed funding. In the last grant period, members of the Translational & Clinical Research Program published 1,157 manuscripts, of which 24.90% represent inter-programmatic and 23.43% resulted from intra-programmatic collaborations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Saint Louis
United States
Zip Code
Eberth, Jan M; Josey, Michele J; Mobley, Lee R et al. (2017) Who Performs Colonoscopy? Workforce Trends Over Space and Time. J Rural Health :
Kuroki, Lindsay M; Frolova, Antonina I; Wu, Ningying et al. (2017) Yield of Cytology Surveillance After High-Grade Vulvar Intraepithelial Neoplasia or Cancer. J Low Genit Tract Dis 21:193-197
Spencer, David H; Russler-Germain, David A; Ketkar, Shamika et al. (2017) CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell 168:801-816.e13
Cusworth, Brian M; Krasnick, Bradley A; Nywening, Timothy M et al. (2017) Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. HPB (Oxford) 19:147-153
Wang, Xuya; Mooradian, Arshag D; Erdmann-Gilmore, Petra et al. (2017) Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. Sci Signal 10:
Knoop, Kathryn A; Gustafsson, Jenny K; McDonald, Keely G et al. (2017) Microbial antigen encounter during a preweaning interval is critical for tolerance to gut bacteria. Sci Immunol 2:
Tang, Rui; Habimana-Griffin, LeMoyne M; Lane, Daniel D et al. (2017) Nanophotosensitive drugs for light-based cancer therapy: what does the future hold? Nanomedicine (Lond) 12:1101-1105
Song, Hao; Ruan, Dan; Liu, Wenyang et al. (2017) Respiratory motion prediction and prospective correction for free-breathing arterial spin-labeled perfusion MRI of the kidneys. Med Phys 44:962-973
Bandyopadhyay, Shovik; Li, Junjie; Traer, Elie et al. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12:e0179558
Lim, Kian-Huat; Langley, Emma; Gao, Feng et al. (2017) A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget 8:24250-24261

Showing the most recent 10 out of 1109 publications